Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

Implementation of genetic testing in breast cancer patients

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Implementation of genetic testing in breast cancer patients ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in...

Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA

Cisplatin versus doxorubicin/cyclophosphamide as neoadjuvant treatment in germline BRCA carriers with HER2-negative BC ( Dr Nadine Tung - Beth Israel Deaconess Medical Center, Boston, USA )

Breast cancer screening and treatment in Brazil

Dr Gustavo Werutsky - Latin American Cooperative Oncology Group, Porto Alegre...

Breast cancer screening and treatment in Brazil ( Dr Gustavo Werutsky - Latin American Cooperative Oncology Group, Porto Alegre, Brazil )

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast...

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA

Long-term influence of oestrogen plus progestin vs oestrogen alone on breast cancer incidence in post-menopausal women ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

Circulating tumour DNA used to predict disease recurrence for early triple...

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center...

Circulating tumour DNA used to predict disease recurrence for early triple-negative breast cancer ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )

Oral paclitaxel with encequidar in metastatic breast cancer

Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras

Oral paclitaxel with encequidar in metastatic breast cancer ( Dr Gerardo Umanzor - Hospital del Valle, San Pedro Sula, Honduras )

Pathologic complete response rates improved with the neoadjuvant and adjuvant...

Prof Peter Schmid - St Bartholomew's Hospital London, London, UK

Pathologic complete response rates improved with the neoadjuvant and adjuvant treatment of pembrolizumab in TNBC patients ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic...

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy

Combining atezolizumab to neoadjuvant chemotherapy does not improve pathologic complete response rates for TNBC patients ( Dr Luca Gianni - San Raffaele Hospital, Milan, Italy )

Breast cancer prevention in high-risk post-menopausal women

Prof Jack Cuzick - Queen Mary University of London, London, UK

Breast cancer prevention in high-risk post-menopausal women ( Prof Jack Cuzick - Queen Mary University of London, London, UK )

More from ecancer